Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2000-04-26
2002-06-04
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001890, C546S124000, C546S132000
Reexamination Certificate
active
06399042
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention includes novel chemical compounds having specific binding in a biological system and capable of being used for positron emission tomography (PET) and single photon emission (SPECT) imaging methods.
The ability of analog compounds to bind to localized ligands within the body makes it possible to utilize such compounds for in situ imaging of the ligands by PET, SPECT and similar imaging methods. In principle, nothing need be known about the nature of the ligand, as long as binding occurs, and such binding is specific for a class of cells, organs, tissues or receptors of interest. PET imaging is accomplished with the aid of tracer compounds labeled with a positron-emitting isotope (Goodman, M. M.
Clinical Positron Emission Tomography
, Mosby Yearbook, 1992, K. F. Hubner et al., Chapter 14). For most biological materials, suitable isotopes are few. The carbon isotope,[
11
C], has been used for PET, but its short half-life of 20.5 minutes limits its usefulness to compounds that can be synthesized and purified quickly, and to facilities that are proximate to a cyclotron where the precursor [
11
C] starting material is generated. Other isotopes have even shorter half-lives. [
13
N] has a half-life of 10 minutes and [
15
O] has an even shorter half-life of 2 minutes. The emissions of both are more energetic than those of [
11
C]. Nevertheless, PET studies have been carried out with these isotopes (Hubner, K. F., in
Clinical Positron Emission Tomography
, Mosby Year Book, 1992, K. F. Hubner, et al., Chapter 2). A more useful isotope,[
18
F], has a half-life of 110 minutes. This allows sufficient time for incorporation into a radio-labeled tracer, for purification and for administration into a human or animal subject. In addition, facilities more remote from a cyclotron, up to about a 200 mile radius, can make use of [
18
F] labeled compounds. Disadvantages of [
18
F] are the relative scarcity of fluorinated analogs that have functional equivalence to naturally-occurring biological materials, and the difficulty of designing methods of synthesis that efficiently utilize the starting material generated in the cyclotron. Such starting material can be either fluoride ion or fluorine gas. In the latter case only one fluorine atom of the bimolecular gas is actually a radionuclide, so the gas is designated
18
F-F. Reactions using
18
F-F as starting material therefore yield products having only one half the radionuclide abundance of reactions utilizing K
18
F as starting material. On the other hand, [
18
F] can be prepared in curie quantities as fluoride ion for incorporation into a radiopharmaceutical compound in high specific activity, theoretically 1.7 Ci
mol using carrier-free nucleophilic substitution reactions. The energy emission of [
18
F] is 0.635 MeV, resulting in a relatively short, 2.4 mm average positron range in tissue, permitting high resolution PET images.
SPECT imaging employs isotope tracers that emit high energy photons (&ggr;-emitters). The range of useful isotopes is greater than for PET, but SPECT provides lower three-dimensional resolution. Nevertheless, SPECT is widely used to obtain clinically significant information about analog binding, localization and clearance rates. A useful isotope for SPECT imaging is [
123
I], a &ggr;-emitter with a 13.3 hour half life. Compounds labeled with [
123
I] can be shipped up to about 1000 miles from the manufacturing site, or the isotope itself can be transported for on-site synthesis. Eighty-five percent of the isotope's emissions are 159 KeV photons, which is readily measured by SPECT instrumentation currently in use.
Use of [
18
F] labeled compounds in PET has been limited to a few analog compounds. Most notably, [
18
F]-fluorodeoxyglucose has been widely used in studies of glucose metabolism and localization of glucose uptake associated with brain activity. [
18
F]-L-fluorodopa and other dopamine receptor analogs have also been used in mapping dopamine receptor distribution.
Other halogen isotopes can serve for PET or SPECT imaging, or for conventional tracer labeling. These include
75
Br,
76
Br,
77
Br and
82
Br which have usable half-lives and emission characteristics. In general, the chemical means exist to substitute any halogen moiety for the described isotopes. Therefore, the biochemical or physiological activities of any halogenated homolog of the described compounds are now available for use by those skilled in the art, including stable isotope halogen homologs. Astatine can be substituted for other halogen isotopes; [
210
At] emits alpha particles with a half-life of 8.3 h. At-substituted compounds are therefore useful for tumor therapy, where binding is sufficiently tumor-specific.
Serotonin transporters (SERTs) are proteins that reside on the membrane of the nerve terminals of the serotoninergic neurons. The SERT serves to remove serotonin from the synapse, a process which helps regulate central nervous system (CNS) serotonin neurotransmission. The serotonin transporter has been convincingly implicated in the pathophysiology of major depression and represents the putative sites of action of the majority of the older and newer generation antidepressants [Murphy, D. L. et al. (1986)
J. Clin. Psychiatr
. 47:(suppl)9-15]. Abnormalities in SERT density in the midbrain and frontal cortex has also been associated with obsessive compulsive disorder. Supporting evidence has, however, been indirect resulting from the study of postmortem tissue and animal and peripheral cell models of transporter cell function and pharmacology. Emission tomography techniques present unique opportunities to define the functional status and pharmacology in the living human brain. The development of serotonin transporter imaging agents labeled with positron emitters has been of recent interest as probes to study the roles of the neuroregulatory site using positron emission tomography (PET) and single-photon emission tomography (SPECT).
Currently, there does not exist a single radiopharmaceutical that can be labeled with either fluorine-18 and iodine-123 amenable for regional distribution that is efficacious in differentiating major depression from other psychiatric disorders. Citalopram [Hume et al. (1991)
Nucl. Med. Biol
. 18:339-351], paroxetine [Suehiro et al. (1991)
Nucl. Med. Biol
. 18:791-796], fluoxetine [Kilbourn et al. (1989)
J. Label. Cmpd. Radiopharm
. 26:412-414], and nitroquipazine [Mathis et al. (1993)
J. Nucl. Med
. 34:7P-8P], potent serotonin transporter ligands, have been radiolabeled with carbon-11 and fluorine-18 as potential radiotracers for localizing and quantifying serotonin transporter sites in the brain using PET. Unfortunately, the in vivo affinity and selectivity for the serotonin transporter of these radiolabeled ligands did not reflect their in vitro potencies as reflected in poor quality images of brain regions rich in serotoninergic neurons. Recently, a series of trans-1,2,3,5,6,10b-hexahydro-pyrrolo(2,1-a]isoquinoline derivatives,have been found to be potent inhibitors with low and subnanomolar affinity for the serotonin transporter [Maryanoff et al. (1987)
J. Med. Chem
. 30:1433-1454]. The most potent inhibitor of the series, trans-1,2,3,5,6,10b-hexahydro-6-[4-(methylthio)phenyl]pyrrolo[2,1-a]isoquinoline(McN-5652Z)(Ki=0.68 nM), has been labeled with carbon-11 for use as a PET radioligand for mapping serotonin transporter sites [Suehiro et al. (1992)
J. Label Cmpd. Radiopharm
. 31:841-848]. Carbon-11 McN-5652Z showed the greatest accumulation in brain regions rich in serotoninergic neurons with greater cortex to cerebellum ratios (4.3 to 1) than previously tested PET serotonin transporter ligands [Suehiro et al. (1993)
J. Nucl. Med
. 34:120-127. However, the very short 20 minute half-life of
Chen Ping
Goodman Mark M.
Emory University
Greenlee Winner and Sullivan P.C.
Hartley Michael G.
LandOfFree
4-fluoroalkyl-3-halophenyl nortropanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-fluoroalkyl-3-halophenyl nortropanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-fluoroalkyl-3-halophenyl nortropanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2947680